HONG KONG – Chinese biotech Zensun (Shanghai) Sci & Tech Co. Ltd., which focuses on innovative therapeutics for cardiovascular and energy metabolic diseases, has plans to raise about ¥500 million (US$76 million) from a consortium of investors, including a state-owned fund.
HONG KONG – Chinese biotech Zensun (Shanghai) Sci & Tech Co. Ltd., which focuses on innovative therapeutics for cardiovascular and energy metabolic diseases, has plans to raise about ¥500 million (US$76 million) from a consortium of investors, including a state-owned fund.
HONG KONG – A consortium of Chinese investors will acquire a 90 percent stake in innovative oncology treatment developer Group NMS Co. Ltd., of Milan, Italy. The total value of the deal, including equity injection and debt restructuring, is around €300 million (US$361.25 million).
HONG KONG – As one of the traditional pharmaceutical companies looking at innovative technologies to fuel its business in a country considering price caps for drugs, Japan's Sumitomo Dainippon Pharma Co. Ltd. has established a new laboratory to further expand efforts in the biopharmaceutical and genomics field.
HONG KONG – Apollobio Corp., of Beijing, has updated and finalized its development and commercialization deal with Inovio Pharmaceuticals Inc., of Plymouth Meeting, Pa., for a vaccine developed for pre-cancers caused by human papillomavirus (HPV).
HONG KONG – As one of the traditional pharmaceutical companies looking at innovative technologies to fuel its business in a country considering price caps for drugs, Japan's Sumitomo Dainippon Pharma Co. Ltd. has established a new laboratory to further expand efforts in the biopharmaceutical and genomics field.
HONG KONG – A consortium of Chinese investors will acquire a 90 percent stake in innovative oncology treatment developer Group NMS Co. Ltd., of Milan, Italy. The total value of the deal, including equity injection and debt restructuring, is around €300 million (US$361.25 million).
